Amarin announces 2022 achievements, 2023 priorities

The company said, "Europe: In 2022, Amarin secured positive pricing and reimbursement decisions in five European markets: England & Wales, Sweden, Austria, Denmark and Finland. Reimbursement negotiations continue to progress in all remaining markets including Spain, Italy, France, Norway and the Netherlands. In 2023, we will focus on opportunities to accelerate revenues in Europe in key launched markets including England & Wales, Northern Ireland, Finland and Sweden and further price negotiations in all markets. United States: The Amarin team achieved four consecutive quarters of revenue stabilization in the U.S. business despite additional generic competition. In 2023, we will maintain our focus on profitability while evaluating and adapting to market conditions. International: Secured six International regulatory approvals, including Hong Kong, Bahrain, Puerto Rico, Saudi Arabia, Australia and Switzerland. In 2023, we will continue to progress international regulatory filings and support approval processes in up to 9 countries, including China and New Zealand. Data Evidence & Pipeline Advancement: Amarin made progress with our fixed-dose combination program for icosapent ethyl, including initiating the process to seek scientific advice from the European Medicines Agency and we look forward to sharing additional updates in 2023."